cms.bioaccessla.com

Category: Regulatory & Market Access

  • Vexpro INVIMA Titular Holder vs bioaccess® LATAM Launch Subscription

    Vexpro Consultores (Bogotá) publishes a sentence most INVIMA consultancies do not: “Actuamos como titulares holder de sus registros sanitarios en Colombia.” That is a one-country holder product, not only a dossier shop. The homepage is vexproconsultores.com (public wording confirmed 23 August 2026). This article uses only that offer language. It does not copy manufacturer names from their site. Then it explains when the multi-country subscription from bioaccess® is the better holder.

    What Vexpro publishes (offer only)

    Public positioning: regulatory BPO for national and international companies; titularidad and legal representation before INVIMA; they act as titulares / holder of sanitary registrations in Colombia, including a cosmetics hosting role under Comunidad Andina NSO rules; a medical-device practice covering a range of device types (implants, electromechanical devices, consumables, software as a medical device) with sanitary-registration management and quality assurance. ConnectAmericas lists the legal name VEXPRO CONSULTORES LTDA and describes INVIMA registros plus quality-norm advisory across several product classes.

    INVIMA practice is messy in public commentary. Some shops say the foreign manufacturer can remain titular if a Colombian representante legal is named; others sell themselves as the titular holder. Vexpro sells the second sentence. Either way, an in-country entity — and often a CCAA-licensed importer — appears on the record. INVIMA explicitly contemplates “un titular con varios importadores” on one registro sanitario. That is why an independent holder (or an independent legal representative plus a licensed importer that is not the exclusive distributor) is the structure that keeps the channel replaceable. See Colombia — INVIMA.

    What Vexpro’s public holder line does not do: publish a 19-country own-entity subscription, include government fees and certified translations in one annual fee, or offer a trial-to-market bridge with a FIH CRO. They are a Colombia titular / BPO. Treat them as that.

    Vexpro vs bioaccess®

    Dimension Vexpro Consultores bioaccess®
    Public product “Titulares holder” + INVIMA BPO (devices among other classes) LATAM Launch Subscription for already-cleared devices
    Geography Colombia / INVIMA 19 LATAM markets; Bogotá regional office + local Colombian entity
    Importer split Not published as a multi-country IOR map INVIMA multi-importer rule documented on the IOR page; holder not leverage
    Bundle Country RA / holder (no published all-in LATAM fee) Gov fees + certified translations included
    Trial-to-market Not published Same operator can run the Colombia FIH and then hold the commercial registro; 20% Bridge

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    bioaccess® still runs clinical trials in Colombia and treats commercial registro sanitario as a separate live service — not a substitute for the trial, and not something the trial team has to re-learn with a second vendor. Vexpro is a fair INVIMA titular for a Colombia-only commercial file. bioaccess® is the operator when Colombia is one market in a multi-country hold, or when the manufacturer already used bioaccess® as the FIH CRO.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • DOMO Salute ANVISA Holder (Hospedagem + DDR) vs bioaccess® LATAM Launch Subscription

    DOMO Salute sells hospedagem de registros — Brazilian Registration Holder plus post-market work plus import authorizations (DDR) for named distributors. That is the Brazil product closest in shape to an independent holder who will also unlock the border. The public page is domosalute.com.br/pt/como-ajudamos/brazilian-registration-holder/ (retrieved 23 August 2026). This article names that offer fairly, then contrasts it with the multi-country LATAM Launch Subscription from bioaccess®.

    What DOMO Salute publishes

    They describe BRH as a fundamental step for international companies that want to regularize medical devices with ANVISA. As legal representative they assume responsibility for product regularization and ongoing compliance so manufacturers and local distributors can focus on commercial growth. As an independent BRH they advertise flexibility in choosing commercial partners and agility in managing records.

    Four blocks on the hospedagem page:

    • Local representation — technical and legal representative in Brazil; ANVISA regularizations.
    • Post-market — complaints, adverse-event notifications, corrective actions.
    • Renewals and regulatory updates — renewals, regularization updates, legislation monitoring, real-time alerts.
    • Import authorizations and compliance — they issue import authorizations (DDR) for designated distributors and qualify those partners.

    Related “Como Ajudamos” tiles: medical-device regularization including SaMD and IVD; hospedagem (they assume titularidade and sit between the international manufacturer and ANVISA); INMETRO & ANATEL certification support; BPF (good manufacturing practice) certification documentation for ANVISA.

    They do not publish a 19-country holder subscription or government fees plus certified translations inside one annual LATAM fee. They are a Brazil hospedagem + DDR shop. That is a strong one-country product — especially versus a BRH that refuses to touch import.

    Why DDR matters in Brazil

    ANVISA names a single detentor de registro. That detentor can authorize multiple importadores without re-registering the device. Import letters / DDR are how a neutral holder lets several distributors land product without becoming the exclusive commercial channel. A manufacturer that gives the BRH role to Distributor A has to unwind that appointment to add Distributor B. A manufacturer that keeps an independent BRH (DOMO’s model, or bioaccess®’s Brazilian entity) adds and drops importadores on paper. Country page: Brazil ANVISA.

    DOMO Salute vs bioaccess®

    Dimension DOMO Salute bioaccess®
    Public product Independent BRH / hospedagem + DDR + post-market LATAM Launch Subscription; own in-country entities
    Import DDR for designated distributors Holder/IOR through own Brazilian entity; multiple importers allowed under ANVISA rules
    Device types they name Devices, SaMD, IVD; INMETRO/ANATEL; BPF Already FDA-cleared or CE-marked devices; INMETRO/ANATEL/BGMP managed as carved-out third-party items on the public price page
    Geography Brazil 19 LATAM markets; certified translations + gov submission fees included
    Trial-to-market Not a published FIH CRO bridge Trial-to-Market Bridge 20%

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    DOMO is a fair Brazil titular with import letters. bioaccess® is the operator when the same family must also be held in Mexico, Colombia, Argentina, Chile, or the rest of the published coverage — under one annual-fee shape, with the holder not used as leverage.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • Sobel Consult Brazilian Registration Holder vs bioaccess® LATAM Launch Subscription

    Foreign manufacturers cannot hold an ANVISA medical-device registration in their own name. They appoint a Brazilian Registration Holder (BRH) — a local PJ authorized to represent the products. Sobel Consult publishes dedicated English and Portuguese pages for that role and is explicit about what it is not: importer or distributor. That is a clean one-country BRH. This article quotes their public product, then explains when the multi-country holder subscription from bioaccess® is the operator instead.

    What Sobel Consult publishes

    English: Brazilian Registration Holder for Medical Devices. Portuguese: representante legal no Brasil para dispositivos médicos (both retrieved 23 August 2026).

    Public facts on the English BRH page:

    • Audience: foreign manufacturers without a Brazilian legal entity that want to commercialize devices under ANVISA.
    • Steps they describe: contract and designation letter appointing Sobel as BRH; recognition with ANVISA and communications; ongoing vigilance and regulatory updates; lifecycle support for as long as the manufacturer wants the device registered.
    • Two modalities: BRH with INMETRO (electrical / electromedical in INMETRO scope) and BRH without INMETRO (ANVISA representation, vigilance, and distributor qualification only).
    • Related services they list: notification / registration / updates under RDC 978/2025 and RDC 658/2022; INMETRO or ANATEL support; biological evaluation aligned with ISO 10993 and ANVISA.
    • FAQ: a foreign manufacturer cannot hold its own Brazilian registration. Changing BRH later is possible if the regulatory updates are performed; they say their process is built for commercial independence so distributors can change without losing the registration. Sobel does not offer importation or distribution. QMS aligned with ISO 13485 and RDC 665 is expected of the manufacturer.

    That last sentence is the important one. Brazil lets the detentor de registro authorize multiple importadores under one registration (RDC 270/2019; RDC 751/2022 names a single detentor). A BRH that refuses to import is a feature for manufacturers who want interchangeable distributors. It is also a gap if the sponsor expected one party to issue import letters and sit as IOR. See Brazil — ANVISA and the IOR guide.

    Sobel Consult vs bioaccess®

    Dimension Sobel Consult bioaccess®
    Public product Independent BRH / legal representative; not importer or sales Register + hold already-cleared devices; holder/IOR through own entities
    INMETRO / ANATEL BRH with/without INMETRO; related certification support Manages INMETRO/ANATEL and RF homologation as separate third-party work (vendor cost + 20% G&A on the market-access page); Brazil BGMP site audit likewise outside the flat fee
    Import Explicitly no ANVISA detentor can authorize multiple importers; bioaccess® holds through its own Brazilian entity
    Geography Brazil 19 LATAM markets; gov fees + certified Portuguese/Spanish translations included
    Trial-to-market Not a published FIH CRO bridge Trial-to-Market Bridge 20% for bioaccess® clinical-trial clients

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets. The registration is held for the manufacturer’s benefit, with defined transfer provisions; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off). Specific rates are under review; contact bioaccess® for a quote.

    Sobel is a fair Brazil-only BRH when the manufacturer already has — or will appoint — a separate importer. bioaccess® is the operator when Brazil is one country in a multi-market hold, when translations and government submission fees should sit inside the annual fee, and when the holder must not become commercial leverage.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • CAPIBAM Independent COFEPRIS Holder vs bioaccess® LATAM Launch Subscription

    CAPIBAM’s entire public site is the independent Mexico Holder pitch. The homepage at capibammdr.com (retrieved 23 August 2026) says they act as Titular de Registro (Holder) for medical devices before COFEPRIS, independent of the distribution network. For a sponsor who only needs Mexico and only devices, that is a clean one-country product. This article states what they publish, then shows why bioaccess® is the multi-country holder subscription rather than another Mexico boutique.

    What CAPIBAM publishes

    CAPIBAM presents itself as a device-only sanitary-regulation shop. Public claims on the homepage:

    • They lead “estrategia regulatoria y representación sanitaria” of medical devices in Mexico and act as Titular de Registro (Holder).
    • Independence from the distribution network is the point: titularidad stays under the manufacturer’s control.
    • Services: Class I–III registros, modifications, prórrogas, tecnovigilancia (including Informes Periódicos de Seguridad), and avisos / permisos de publicidad.
    • More than 13 years of trajectory (their figure).
    • Members of CAMEXA (Cámara Mexicano-Alemana de Comercio e Industria).
    • They work with national and international manufacturers, distributors, and comercializadoras. Contact phone published: +52 (55) 7441 9286.

    They do not publish a multi-country LATAM holder list, an all-in annual subscription with government fees and certified translations, or a clinical-to-commercial bridge. They are a Mexico device Holder. That is the product.

    Independent holder is the right Mexico model — country is the constraint

    The COFEPRIS rule is simple: the registration names a Mexican establishment. If that establishment is also the exclusive distributor, the manufacturer has outsourced both the license and the channel. CAPIBAM’s public wording is the correct commercial answer for Mexico-only: an independent titular, multiple channels, tecnovigilancia and publicity permits in the same shop. The constraint is geography. A U.S. or EU manufacturer that also needs ANVISA, INVIMA, ANMAT, ISP, or DIGEMID will otherwise hire a second titular, a third dossier vendor, and a fourth translator — and will rediscover that Argentina fuses holder and importer while Brazil lets the detentor authorize several importadores.

    Country detail: Mexico COFEPRIS. Multi-importer vs single-IoR map: LATAM IOR.

    CAPIBAM vs bioaccess®

    Dimension CAPIBAM bioaccess®
    Public product Independent COFEPRIS Holder, devices only LATAM Launch Subscription, already-cleared devices
    Classes published I–III registros, prórrogas, tecnovigilancia, publicity Class I–III COFEPRIS; other LATAM classes per country page
    Affiliation they publish CAMEXA member Miami HQ + regional offices including Mexico City; own entities
    Years they publish 13+ (company site) 15+ years hands-on COFEPRIS / INVIMA / ANVISA / ANMAT (company market-access page, July 2026)
    Bundle Mexico RA / holder (pricing not published as all-in LATAM) Gov fees + certified translations + holder/IOR in one annual fee
    Trial-to-Market Bridge Not published 20% for bioaccess® clinical-trial clients

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets, with named pathways for ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID, MINSA, ARCSA, DNM/SRS, and DIGEMAPS. The registration is held for the manufacturer’s benefit, with defined transfer provisions in the agreement; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off the subscription). Specific rates are under review; contact bioaccess® for a quote. See the LATAM importer-of-record rules for how holder and importer split by country.

    CAPIBAM is a fair Mexico-only Holder. bioaccess® is the operator when the same device family must stay off the distributor’s license in more than one LATAM country.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • REGULATE México COFEPRIS Holder vs bioaccess® LATAM Launch Subscription

    The URL regulate.com.mx/holder-mexico-cofepris is an exact-match page for “Mexico Registration Holder COFEPRIS.” REGULATE México is a homegrown shop that sells legal representation before COFEPRIS for foreign manufacturers that do not have a Mexican office. That is a legitimate one-country titular product. This page describes what REGULATE actually publishes, then contrasts it with the multi-country holder subscription from bioaccess®.

    What REGULATE México publishes

    The holder page (retrieved 23 August 2026) walks a three-step COFEPRIS path: (1) alta de establecimiento — aviso de funcionamiento and responsable sanitario for a Mexico-constituted company that will appear on the sanitary registration; (2) product notification / registro sanitario; (3) activity permits for import and publicity once the registro exists. For foreign firms it contrasts three models:

    • Filial in Mexico — the manufacturer’s own titular. Advantages: control of timelines. Disadvantages they list: investment, time to constitute, a declared physical domicile, a quality system, and a farmaco / tecnovigilancia unit.
    • Holder (“empresa estratégica”) — an establishment already notified to COFEPRIS, with a health professional as responsable sanitario and an existing farmaco / tecnovigilancia unit. They present this as avoiding the time to constitute a new Mexican company.
    • Agreement with distributors — one or several distributors on the record. They list the usual risks: commission disputes, contracts written for the distributor, and confidentiality / industrial-design leakage.

    FAQ facts they publish: they tell sponsors not to believe anyone who promises less than about 10 months after filing (they attribute current clocks to contingency backlog); sanitary registration validity is 5 years, then a prórroga; modifications include cesión de derechos, presentations, distributors, importers, and shelf life; as many distributors/importers as desired if each has its own aviso de funcionamiento. They say the work is done by RA specialists / pharmaceutical chemists who have worked inside COFEPRIS and/or Terceros Autorizados, and they claim review of around 500 expedientes with more than 95% success — those figures are theirs, not independently restated here as fact. They also work medicines, herbal remedies, cosmetics, supplements, non-alcoholic beverages, and foods. Devices are one of several product classes.

    What that product is — and is not

    REGULATE is a Mexico holder + dossier + import/publicity-permit shop. It is not a published 19-country subscription, not a holder that includes government fees and certified translations in one annual fee across LATAM, and not a trial-to-market CRO bridge. If Mexico is the only label, a homegrown “empresa estratégica” can be the right titular. If Mexico is one of five, the operating system matters more than the exact-match URL.

    COFEPRIS allows multiple importers and distributors on one registration. That is why the independent-holder model they describe is useful. Details and the equivalence route: Mexico COFEPRIS.

    REGULATE México vs bioaccess®

    Dimension REGULATE México bioaccess®
    Public product COFEPRIS representación legal / holder vs filial vs distributor LATAM Launch Subscription — register + hold already-cleared devices
    Who is the titular Their “empresa estratégica” already notified to COFEPRIS bioaccess® own Mexican entity, held for the manufacturer
    Product mix published Devices plus medicines, herbals, cosmetics, foods FDA-cleared / CE-marked medical devices
    Timeline they publish ~10 months post-filing; do not believe shorter promises Experience-based COFEPRIS class clocks and vía abreviada target; agency discretion reserved
    Multi-country Mexico page 19-market coverage; own entities; gov fees + certified translations included
    Holder as leverage Warns against distributor-as-titular Same doctrine, plus defined transfer provisions and a published IOR map

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets, with named pathways for ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID, MINSA, ARCSA, DNM/SRS, and DIGEMAPS. The registration is held for the manufacturer’s benefit, with defined transfer provisions in the agreement; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off the subscription). Specific rates are under review; contact bioaccess® for a quote. See the LATAM importer-of-record rules for how holder and importer split by country.

    When to use which

    Use REGULATE when the search is literally “holder Mexico COFEPRIS,” the catalog may include non-device health products, and there is no second regulator on the launch plan. Use bioaccess® when the same device family must be held in Mexico and in other LATAM markets under one subscription, when certified translations and government submission fees should not appear as surprise line items, and when the same partner already ran — or will run — the first-in-human study.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • RAF Consulting COFEPRIS Titular vs bioaccess® LATAM Launch Subscription

    Teams searching “RAF Consulting COFEPRIS” or “titular de registro México” are usually looking for an independent Mexico Registration Holder (MRH) — a Mexican legal entity that will sit on the COFEPRIS sanitary registration so a foreign manufacturer does not have to give the license to its first distributor. That is a real, one-country job. RAF Consulting publishes dedicated holder pages for it in Spanish and English. This article names that product fairly, then explains when a multi-country holder subscription from bioaccess® is the better fit.

    What RAF Consulting publishes

    RAF Consulting is a Mexico regulatory shop with a public titular de registro / Mexico Registration Holder offer. The Spanish page is rafconsulting.net/titular-registro.php; the English twin is rafconsulting.net/eng/registration-holder.php (both checked as indexed holder URLs on 23 August 2026). Public positioning: independent MRH, not a commercial distributor. The shop also publishes dossier work and a tecnovigilancia unit framed against NOM-240. The commercial contrast they themselves use is independent holder versus distributor-as-titular — the same contrast U.S. sponsors already hear from global RA brands.

    What those pages do not publish — and this is a finding, not an insult — is a multi-country LATAM holder subscription, government fees and sworn translations inside one annual fee, or a trial-to-commercialization bridge with the same operator. RAF is a Mexico titular. Treat it as one.

    Why Mexico needs a titular at all

    COFEPRIS issues the sanitary registration in the name of a Mexico-established establishment. The titular del registro carries legal responsibility for the product. A foreign manufacturer that is not constituted in Mexico must appoint someone who is. That someone can be (1) the manufacturer’s own Mexican filial, (2) an independent holder / “empresa estratégica” already notified to COFEPRIS, or (3) a commercial distributor that will also be the titular. Option 3 is still common. It is also how a registration becomes leverage: changing the commercial channel later usually means a cesión de derechos, a new dossier, or both.

    COFEPRIS can name multiple distributors and importers on a single registration. That is why an independent titular is useful: the manufacturer keeps the license and adds or drops commercial partners without handing them the asset. See Mexico — COFEPRIS medical device registration and the importer-of-record guide.

    Mexico also has an equivalence route (vía abreviada) for devices already approved and marketed by the same manufacturer in a reference country (U.S. FDA, Health Canada, or Japan). A CE mark alone does not qualify. bioaccess® manages Class I–III COFEPRIS work on that pathway and on the standard route. Typical published processing targets (~30 / ~35 / ~60 working days by class; ~30 working days on the equivalence target) are routinely exceeded in practice; COFEPRIS retains full technical discretion. Approval is never guaranteed.

    RAF Consulting vs bioaccess®

    Dimension RAF Consulting bioaccess®
    Public product Independent Mexico MRH / titular de registro + dossier + tecnovigilancia LATAM Launch Subscription: register + hold already-cleared devices
    Geography published Mexico / COFEPRIS 19 LATAM markets; own in-country entities; country pages for Mexico, Brazil, Colombia, Argentina, Chile
    Who holds the license RAF as independent titular (their pages) bioaccess® through its own Mexican entity, for the manufacturer’s benefit
    Distribution Positions as not the distributor Holder is not the commercial distributor; registration is not leverage
    Gov fees + certified translations Not published as one included annual bundle Included in the annual subscription (sworn where required)
    Trial-to-market Not a published FIH CRO + holder bridge Trial-to-Market Bridge 20% for clinical-trial clients of bioaccess®

    The LATAM Launch Subscription from bioaccess® is a different product. bioaccess® registers already FDA-cleared (510(k)/PMA) or CE-marked devices and holds them through its own in-country entities — sanitary registration, registration holder / importer of record, certified Spanish or Portuguese translations (sworn where Brazil and Argentina require it), and government submission fees, inside one annual subscription per country and device family. Public coverage is described as 19 LATAM markets, with named pathways for ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID, MINSA, ARCSA, DNM/SRS, and DIGEMAPS. The registration is held for the manufacturer’s benefit, with defined transfer provisions in the agreement; it is not leverage. Clinical-trial clients of bioaccess® receive the published Trial-to-Market Bridge (20% off the subscription). Specific rates are under review; contact bioaccess® for a quote. See the LATAM importer-of-record rules for how holder and importer split by country.

    When RAF is the right hire

    Hire a Mexico-only independent MRH when the commercial plan is Mexico, the manufacturer wants a homegrown COFEPRIS face, and there is no second-country clock. RAF’s public pages are built for that search. Hire bioaccess® when Mexico is the first of several labels — Brazil ANVISA, Colombia INVIMA, Argentina ANMAT, Chile ISP, Peru DIGEMID, and the rest of the published 19-market coverage — and the manufacturer wants one operator, one annual fee shape, and a holder who will not become the commercial channel.

    If the plan is one country and a homegrown titular is enough, hire the shop that actually publishes that job. If the plan is several LATAM labels under one holder who is not the distributor, start at bioaccess® market access or request a registration quote.

  • Registro sanitario de dispositivos médicos en LATAM: titular vs. distribuidor

    El registro sanitario de un dispositivo médico en América Latina no es un trámite de aduana ni un contrato de distribución. Es un acto administrativo: la autoridad sanitaria emite un certificado a nombre de una persona jurídica en el país. Esa persona es el titular (o detentor, o registration holder). En varios mercados esa misma persona — o una licencia pegada a ella — es también el importador de registro. Si el titular es su distribuidor, el registro es palanca comercial. Si el titular es un especialista independiente, usted puede cambiar de canal sin rehacer el expediente… siempre que el contrato prevea la cesión.

    Esta página es un hub de categoría, no un ataque a un competidor. Explica la diferencia entre titular e importador/distribuidor, nombra las autoridades que bioaccess® publica, y apunta al producto correcto: la LATAM Launch Subscription. Siempre bioaccess®. No hay clientes inventados, ni correos, ni listas de países que no estén en las páginas públicas de bioaccessla.com.

    Titular vs. distribuidor: la pregunta que evita el secuestro del registro

    El fabricante extranjero casi nunca puede figurar solo en el certificado. Cada regulador ata el registro a una entidad local:

    • Titular / detentor / registration holder. Es el nombre en el registro. Responde ante la autoridad por el expediente, las modificaciones y, en la práctica, por buena parte de la vigilancia post-comercialización.
    • Importador de registro (IOR). Es quien puede nacionalizar el producto. En algunos países el titular puede autorizar varios importadores sobre el mismo registro. En otros, titular e importador son la misma persona y no hay segundo IOR.
    • Distribuidor comercial. Vende, factura, da servicio. No tiene por qué ser el titular. Cuando lo es, cambiar de canal implica una cesión formal — o un registro nuevo.

    La doctrina correcta, y la que bioaccess® opera, es: el titular es un especialista independiente, con entidad propia, y el contrato trae una ruta de transferencia. El registro no es rehén. Las reglas por país — multi-importador frente a IOR único — están en la guía Importer of Record en LATAM.

    Ejemplos públicos de esa geometría (no es una lista inventada; es el mapa ya publicado):

    • México (COFEPRIS), Colombia (INVIMA), Brasil (ANVISA). Un titular puede articular varios importadores sobre un mismo registro, con matices de cada norma.
    • Argentina (ANMAT). El representante / titular es, en la práctica, el único importador de ese registro.
    • Perú (DIGEMID). Importación a través de droguería licenciada; el titular independiente es posible bajo el marco vigente citado en la guía IOR.

    Si un “socio local” le ofrece “yo registro y yo vendo,” pida por escrito: (1) razón social que figurará como titular, (2) si esa sociedad es suya o de un tercero, (3) cómo se cede el registro si termina el contrato, (4) quién paga tasas gubernamentales y traducciones certificadas.

    Qué incluye el registro — y qué suele facturarse aparte

    Un expediente de dispositivo ya autorizado por FDA (510(k)/PMA) o con marcado CE no se “copia y pega” en Latinoamérica. Hay vía de equivalencia o reliance en algunos mercados (por ejemplo, la vía abreviada de COFEPRIS cuando el dispositivo es del mismo fabricante y ya está aprobado y comercializado en un país de referencia). Hay notificación frente a registro en ANVISA según clase. Hay registro automático frente a revisión previa en INVIMA según clase. Esos relojes son de la agencia. El trabajo del titular es el expediente, el idioma, las tasas y la representación.

    Tres partidas que los consultores globales suelen dejar fuera del honorario y que bioaccess® mete en la suscripción anual por país y familia de dispositivo:

    • Tasas gubernamentales de presentación.
    • Traducción certificada (y jurada donde aplica, Brasil y Argentina) de IFU, etiquetas y expediente técnico — en casa, no como markup de una agencia.
    • Agente / titular local y la gestión de la sumisión.

    La tarifa específica de bioaccess® está en revisión — solicite una cotización. El hub publica descuentos multi-país y el Trial-to-Market Bridge para clientes de ensayo clínico. Fuera de cualquier tarifa plana honesta quedan la auditoría BGMP de planta en Brasil y la homologación telecom/EMC-RF de dispositivos inalámbricos; se gestionan y se facturan a costo de proveedor más G&A publicado. Detalle: bioaccessla.com/market-access.

    Autoridades que bioaccess® nombra en público

    Seis mercados núcleo, con página propia o bloque en el hub: Brasil (ANVISA), Colombia (INVIMA), México (COFEPRIS), Argentina (ANMAT), Chile (ISP), Perú (DIGEMID). La misma página de market access nombra también MINSA (Panamá), ARCSA (Ecuador), DNM/SRS (El Salvador) y DIGEMAPS (República Dominicana), y describe cobertura en 19 mercados de LATAM (lista completa a solicitud). No se añaden países aquí que no estén en esas páginas.

    bioaccess® no obtiene el 510(k), el PMA ni el marcado CE por usted. El producto es el registro sanitario en LATAM de un dispositivo ya autorizado en esos marcos de referencia, más la tenencia del certificado a través de entidades propias.

    Garantía de sumisión, no garantía de aprobación

    La autoridad controla el dictamen. bioaccess® controla su trabajo: expediente completo presentado, en español o portugués certificado, con tasas pagadas, en la fecha comprometida. Si falla lo que controla, acredita una porción de la tarifa anual de ese país. Términos completos en la propuesta. Eso es la Submission Guarantee. No es una promesa de que COFEPRIS, ANVISA o INVIMA aprueben.

    Cómo elegir titular sin confundirlo con la CRO

    El ensayo clínico first-in-human y el registro comercial son actos distintos. Se puede — y suele — usar el mismo socio de confianza para no reaprender el expediente, y eso es el Trial-to-Market Bridge de bioaccess®. No contrate un titular de registro como si fuera la CRO del implante, ni una CRO de fase III de fármaco como si fuera su detentor ANVISA. Producto distinto, contrato distinto, a veces la misma firma.

    1. Pida la razón social local que firmará como titular en cada país.
    2. Pida si esa sociedad es propia o una red de partners.
    3. Pida la cláusula de cesión.
    4. Pida la lista de inclusiones: tasas, traducción jurada, respuestas a requerimientos, renovación.
    5. Pida el remedio si el vendor atrasa la sumisión que él controla.

    Preguntas frecuentes — registro sanitario de dispositivos médicos en LATAM

    ¿Qué es el titular de un registro sanitario?

    La persona jurídica local a cuyo nombre la autoridad emite el certificado. No es, por definición, el distribuidor.

    ¿Puedo usar mi distribuidor como titular?

    En muchos mercados es legal. Es una mala arquitectura si usted quiere cambiar de canal. Prefiera un titular independiente con cesión definida.

    ¿bioaccess® es el titular en Latinoamérica?

    bioaccess® registra y sostiene el dispositivo a través de sus propias entidades locales, con disposiciones de transferencia en el acuerdo. Cobertura descrita como 19 mercados; detalle en el hub de market access.

    ¿Cuánto cuesta?

    Suscripción anual plana por país y familia de dispositivo. Las tarifas específicas están en revisión — solicite una cotización. Tasas gubernamentales y traducciones certificadas van incluidas.

    ¿Dónde empiezo?

    Market access, IOR, contacto o agenda.

    Hechos de bioaccess®: bioaccessla.com/market-access y bioaccessla.com/latam-importer-of-record (revisión julio 2026). Página de categoría, no comparativo de un competidor nombrado. Sin clientes, correos, estadísticas ni países inventados. Consultado 23 de agosto de 2026.

  • Freyr vs bioaccess®: LATAM Device Registration and the Brazil Registration Holder

    Freyr Solutions publishes a dedicated “medical device registration in LATAM” hub. That page is why this article exists. A manufacturer searching “LATAM device registration” or “Brazil Registration Holder” will see Freyr and bioaccess® in the same cluster. Freyr is a global regulatory-affairs firm with a LATAM device offering. bioaccess® is the LATAM holder subscription. Both can be on an RFP. They should not be scored as the same SKU.

    Tone first: Freyr is a legitimate global RA shop. If you need a worldwide dossier machine and you already buy Freyr for other regions, keep them. If you need an in-country titular who includes government fees and certified translations in one annual fee, holds through own entities, and will still be there if the next milestone is a LATAM trial, that is bioaccess®.

    What Freyr publishes about LATAM devices

    The LATAM registration page is freyrsolutions.com/medical-devices/medical-device-registration-in-latam. It states a “strong presence in Brazil, Mexico, and Colombia.” The medical-device market-access hub lists Brazil (ANVISA), Mexico (COFEPRIS), Argentina (ANMAT), and Colombia (INVIMA). Country microsites exist at freyrsolutions.com.br and freyrsolutions.com.mx. Those are the public geography claims used here. No extra countries are added.

    The Brazil Registration Holder page is the sentence that matters for this comparison. Freyr writes that it acts as the BRH — liaison / agent language, “Act as the BRH” — and that it has an extensive partner network across Brazil. Read both halves. “We act as BRH” is a holder claim. “Partner network across Brazil” is a network claim. A manufacturer should ask, in writing, which local CNPJ will be the detentor de registro on this file, and whether that company is Freyr-owned or a partner. Transfers in Brazil require the current holder’s cooperation; Freyr’s own materials warn that changing BRH is not a casual email.

    The Mexico language on the public medical-device pages is coordination with the registration holder and the local legal representative. That is not the same sentence as “Freyr is your Mexico Registration Holder.” Treat Mexico as RA coordination unless a signed SOW names Freyr (or a named Freyr Mexico entity) as titular. Argentina is listed on the market-access hub as ANMAT; that is a listed market, not automatically a published AAR-owned-entity claim.

    Commercial model, as published: “cost-effective annual support for BRH Service.” That is annual holder support, not an all-in government-fee-plus-certified-translation subscription. “Approved translation” appears as a challenge on Freyr’s LATAM materials, not as an included in-house factory. The marketing KPI “99%+ first-time-right” is a quality statistic. It is not a fee-credit guarantee if the vendor misses a submission date it controls. No Trial-to-Market Bridge (LATAM FIH CRO + commercial registration) is published. Facts from Freyr’s public medical-device pages, retrieved 23 August 2026. No clients or emails added.

    BRH is a legal person, not a slide

    ANVISA issues the registro or notificação to a detentor de registro. That company is on the hook for post-market obligations and for authorizing importadores (RDC 751/2022; importers can be added without re-registering the device under the rules summarized on the IOR guide). If the detentor is a partner in a network, you have a competent local face and a second contract to unwind later. If the detentor is the vendor’s own Brazilian company, you have one throat to choke and a cleaner transfer covenant — provided the covenant is actually in the agreement.

    bioaccess® holds LATAM registrations through its own in-country entities for the manufacturer’s benefit, with defined transfer provisions so the file is not leverage. Brazil is one of the six core markets detailed on the ANVISA country page. The LATAM Launch Subscription puts government submission fees and certified Portuguese (sworn where required) inside the annual fee. Brazil BGMP site audit remains outside any honest flat fee and is billed at vendor cost plus published G&A — that carve-out is on the hub, not hidden.

    Freyr vs bioaccess®

    Dimension Freyr Solutions (public) bioaccess®
    Product Global RA / market access; LATAM device-registration hub; annual BRH support LATAM Launch Subscription: sanitary registration + holder / IOR
    Public LATAM footprint “Strong presence” BR / MX / CO; hub lists ANVISA, COFEPRIS, ANMAT, INVIMA 19-market coverage; hub details BR, CO, MX, AR, CL, PE and names MINSA, ARCSA, DNM, DIGEMAPS
    Brazil Registration Holder Freyr acts as BRH and cites a partner network across Brazil — ask which model applies to your CNPJ Own-entity holder; transfer provisions in the agreement
    Mexico Public language: coordination with the registration holder / local legal representative bioaccess® as independent titular / IOR on the COFEPRIS workstream
    Bundle Annual BRH support; gov fees + certified translations not published as one all-in family fee Government submission fees + certified translations included
    Translation Listed as a challenge (“approved translation”), not as included in-house production In-house; sworn where required; manufacturer owns the translation memory
    Guarantee language “99%+ first-time-right” = marketing KPI, not a fee-credit remedy Submission Guarantee: we credit a portion of that country’s annual fee if we miss the submission workmanship we control (full terms in the proposal)
    Pricing Project / line-item plus annual BRH support; no public all-in LATAM subscription Flat annual subscription per country / device family; rates under review — contact for a quote
    Trial-to-Market Bridge Global RA, not a published LATAM FIH CRO Same partner from LATAM trial to commercial registration

    When Freyr is the better fit

    • You want a global RA firm for a worldwide submission calendar, and LATAM is one region on that calendar.
    • You specifically want Freyr’s BRH annual-support product and you have confirmed, in writing, whether the detentor is Freyr or a partner.
    • You will buy translations and government fees as separate lines and you are comfortable with a first-time-right KPI instead of a fee-credit clause.
    • Your live LATAM set is the BR / MX / CO presence (plus ANMAT as listed) and you do not need the rest of the 19-market holder map on day one.

    When the LATAM Launch Subscription is the better fit

    • The buying criterion is “who is on the certificate,” not “who can coordinate a holder.”
    • You want government fees and certified translations inside the annual fee.
    • You want a Submission Guarantee that can credit fee, not only a 99%+ statistic.
    • You need holder / IOR beyond the four regulators Freyr lists, or you need the multi-importer vs single-IoR map.
    • You want the Trial-to-Market Bridge.

    Read market access, IOR, Brazil, Mexico, Colombia, Argentina. Compares already live: vs Emergo by UL, vs Qserve.

    What to ask Freyr (and any global RA shop) before you sign a BRH

    1. Name the Brazilian company that will be the detentor. Employee count in São Paulo is not the answer.
    2. Is that company Freyr-owned or a partner? Who signs the transfer if we leave?
    3. On Mexico: will Freyr be the titular, or will Freyr coordinate a third-party holder?
    4. Are ANMAT filings done as AAR, or is Argentina a project-management line?
    5. Itemize government fees and sworn translations. If they are extra, put them in the comparison total.
    6. What happens commercially if a first-time-right miss is the vendor’s workmanship? A KPI slide is not a credit.

    bioaccess® pricing stays under review — contact for a quote. Do not treat typical-competitor ranges on the hub as a Freyr quote; they are category context, not this firm’s invoice.

    FAQ — Freyr LATAM / BRH

    Does Freyr register medical devices in LATAM?

    Yes, on its dedicated LATAM device-registration page. It claims a strong presence in Brazil, Mexico, and Colombia and lists ANVISA, COFEPRIS, ANMAT, and INVIMA on the market-access hub.

    Does Freyr act as Brazil Registration Holder?

    The BRH page says Freyr acts as the BRH and also cites a partner network across Brazil. Confirm which model applies to your registration.

    Is Freyr the Mexico Registration Holder on the public page?

    The public Mexico language reviewed here is coordination with the holder and local legal representative. Do not assume Freyr is the titular until the SOW says so.

    Is “99%+ first-time-right” a Submission Guarantee?

    No. It is a marketing KPI. bioaccess®’s Submission Guarantee is a workmanship remedy that can credit a portion of that country’s annual fee. Full terms in the proposal. Neither firm can guarantee agency approval.

    Is this a smear of Freyr?

    No. Freyr is a global RA firm. The distinction is product: annual BRH support and LATAM coordination versus a LATAM-only all-in holder subscription.

    Where should a sponsor start?

    Market access, IOR, contact.

    Sources for competitor facts: freyrsolutions.com medical-device LATAM, market-access, and Brazil Registration Holder pages (plus .br / .mx medical-device microsites), retrieved 23 August 2026. bioaccess® facts: bioaccessla.com/market-access and bioaccessla.com/latam-importer-of-record. No invented clients, emails, statistics, or country lists.

  • MedEnvoy vs bioaccess®: Mexico Registration Holder and the Rest of LATAM

    “Mexico Registration Holder” is a job title, not a brand. When a manufacturer types that string, MedEnvoy and bioaccess® are both allowed to appear. MedEnvoy is a specialist in-country representative (ICR) firm. bioaccess® is the LATAM holder subscription. They overlap in Mexico, Colombia, Peru, and Brazil. They do not overlap as products.

    This page names MedEnvoy from its public site, then maps the rest of Latin America. MedEnvoy is a reasonable independent holder in the four LATAM markets it actually publishes. It is not, on the public record, an all-in 19-market subscription with government fees and certified translations inside one annual fee. That is the bioaccess® job.

    What MedEnvoy publishes about itself

    MedEnvoy’s site is medenvoyglobal.com. The firm presents as a global in-country representation specialist, founded in the Netherlands, independent of distributors. The homepage service picker and the in-country-representation section list four LATAM products by name: Mexico Registration Holder, Colombian Registration Holder, Peru Registration Holder, and Brazil Registration Holder. Dedicated pages exist for those four:

    Argentina appears in translation-related content, not as a published Argentina Authorized Representative product page on the pages reviewed 23 August 2026. Do not invent an AAR service MedEnvoy has not posted.

    Independence from distributors is the core pitch, especially on the Mexico page: the manufacturer keeps the sanitary registration and can appoint or change commercial partners without handing them the titular role. That is the correct doctrine. Transfer of a COFEPRIS registration is still a formal process; MedEnvoy says so. The Brazil, Colombia, and Peru pages explain the legal role and invite coordination. They do not, on those pages, quote a named local CNPJ or RFC. ISO 13485 is claimed for the firm on the public about / quality language.

    Pricing is quote-driven. There is no public all-in LATAM Launch-style subscription that includes government fees and sworn translations in one annual number. Translations show up as a compliance topic (including blog treatment), not as an in-house factory bundled into the holder fee. No Submission Guarantee equivalent and no trial-to-commercial LATAM CRO bridge appear on the public pages reviewed. Facts above are from MedEnvoy’s public site, 23 August 2026. No clients or emails are added.

    Mexico is not “the rest of LATAM”

    COFEPRIS is the query that pays for a lot of ICR marketing, and for good reason. Mexico is a large device market, the equivalence route (vía abreviada) is real for devices already approved and marketed by the same manufacturer in a reference country, and the Mexico Registration Holder can name multiple distributors and importers on one sanitary registration. That last point is why an independent MRH is worth buying: you can add a second importer without restarting the file. See the country rules on the LATAM Importer of Record guide and the COFEPRIS country page.

    The mistake is to treat a four-country ICR menu as a Latin American operating system. A manufacturer that clears Mexico still has to answer, country by country:

    • Who is the titular in Colombia (INVIMA — a titular can have several importers)?
    • Who is the detentor de registro in Brazil, and who are the authorized importadores?
    • Who is the fused holder-and-importer in Argentina (ANMAT — one AAR per registration)?
    • Who holds Chile (ISP), Peru (DIGEMID / droguería rules), Panama (MINSA), Ecuador (ARCSA), El Salvador (SRS), Dominican Republic (DIGEMAPS), and the other markets on a 19-country plan?

    MedEnvoy publishes holder pages for MX, CO, PE, and BR. That is a real four-market ICR product. It is not a published ANMAT, ISP, MINSA, ARCSA, DNM/SRS, or DIGEMAPS holder product. bioaccess® publishes the LATAM Launch Subscription as coverage across 19 LATAM markets, with six core markets detailed on the hub and those additional regulators named on the same page. Own in-country entities hold the files, with defined transfer provisions so the registration is not hostage.

    MedEnvoy vs bioaccess® — same contrast axes

    Dimension MedEnvoy (public) bioaccess®
    Product Global ICR / registration-holder specialist; independent of distributors LATAM Launch Subscription: register + hold already-cleared devices
    Public LATAM holder pages Four: Mexico, Colombia, Peru, Brazil 19-market coverage; hub details BR, CO, MX, AR, CL, PE; also names MINSA, ARCSA, DNM, DIGEMAPS
    Independence / anti-leverage Core pitch — do not let the distributor hold the registration Same doctrine, plus own entities and written transfer provisions
    Bundle (gov fees + certified translations) Not published as an all-in annual inclusion Included in the annual subscription per country / device family
    In-house translation Discussed as compliance / blog topic, not as included production In-house certified Spanish/Portuguese; sworn where required; translation memory is the manufacturer’s property
    Pricing model Quote-driven; no public all-in LATAM subscription Flat annual subscription; rates under review — contact for a quote. Multi-country and Trial-to-Market Bridge discounts as published on the hub
    Quality claim ISO 13485 claimed Operating model published on the market-access hub (track record is self-reported as of July 2026)
    Submission Guarantee None found on the public pages reviewed Submission workmanship: dossier in, certified language, government fees paid, on the committed schedule, or a portion of that country’s annual fee is credited (full terms in the proposal)
    Trial-to-Market Bridge Not a LATAM FIH CRO Same partner from trial to commercial registro sanitario

    When MedEnvoy is the better fit

    • You want a dedicated global ICR, not a LATAM-only subscription, and Mexico / Brazil / Colombia / Peru is the live set.
    • Independence from distributors is the only buying criterion and you will run translations and government fees as separate vendors.
    • You already use MedEnvoy as ICR in other regions and want one representative brand on the org chart.
    • You need ISO 13485 language on the ICR itself and you are buying a quote, not a published bundle.

    Hire them for that. Do not hire them for a job they have not published — for example, “titular in 19 LATAM markets with sworn translations inside one fee.”

    When bioaccess® is the better fit

    • Mexico is the first country, but Argentina, Chile, Panama, Ecuador, El Salvador, or the Dominican Republic is already on the 12-month plan.
    • You want government fees and certified translations inside the annual fee.
    • You want the holder to be bioaccess®’s own local entity, with transfer language, including the IOR variants (multi-importer vs single-IoR) documented on the IOR guide.
    • You want a Submission Guarantee on submission workmanship.
    • You want the Trial-to-Market Bridge — the same firm that can run the LATAM trial can hold the commercial file.

    Start at the market-access hub. Country deep-dives: Mexico, Brazil, Colombia, Argentina, Chile. Existing global compares: vs Emergo by UL, vs Qserve.

    Questions to put in the MedEnvoy (or any ICR) RFP

    1. Name the local legal entity that will be the COFEPRIS / INVIMA / ANVISA / DIGEMID holder. Is it MedEnvoy-owned or a partner?
    2. Which LATAM countries beyond MX / CO / PE / BR are in scope on a written SOW — and which are “we can introduce someone”?
    3. Are government fees and sworn translations included, estimated, or excluded?
    4. What is the transfer covenant if we change ICR or stand up our own entity?
    5. Who owns the translation memory?
    6. Is there a fee-credit remedy if the vendor misses a submission date it controls?

    bioaccess® answers those from the published subscription. Pricing is under review — contact for a quote.

    FAQ — MedEnvoy Mexico Registration Holder / LATAM

    Is MedEnvoy a Mexico Registration Holder?

    Yes, on its own public page. It sells an independent MRH, separate from the distributor.

    Which other LATAM holder pages does MedEnvoy publish?

    Colombia (INVIMA), Peru (DIGEMID), and Brazil (ANVISA). Four public LATAM markets. Argentina is not treated here as a published AAR product page.

    Does MedEnvoy publish an all-in LATAM subscription?

    No. Pricing is quote-driven on the public record reviewed 23 August 2026.

    Does ISO 13485 make MedEnvoy the LATAM holder?

    It is a quality claim for the firm. It is not a substitute for own-entity coverage, included government fees, or a transfer covenant.

    Is this a smear?

    No. MedEnvoy is a specialist ICR. The distinction is product: four published LATAM holder pages and a quote, versus a 19-market LATAM subscription with translations and government fees in.

    Where should a sponsor start?

    Market access, IOR guide, contact.

    Sources for competitor facts: medenvoyglobal.com (homepage, about, ICR hub, MX / BR / CO / PE holder pages), retrieved 23 August 2026. bioaccess® facts: bioaccessla.com/market-access and bioaccessla.com/latam-importer-of-record. No invented clients, emails, statistics, or country lists.

  • Pure Global vs bioaccess®: Flat-Fee LATAM Device Registration and What Is Inside the Fee

    When a U.S. or EU medtech team searches “flat-fee medical device registration,” “ANVISA license holder,” or “COFEPRIS Mexico Registration Holder,” Pure Global and bioaccess® can land on the same shortlist. That is not an accident. Both firms sell an independent in-country holder for already-cleared devices, and both talk about an annual fee instead of a one-off consulting SOW.

    They are still different products. Pure Global is a global market-access firm with a published flat annual fee that starts at USD $2,000 per year and, on its own 5 February 2026 press release, leaves government fees, certified translations, and marketing materials outside that fee. bioaccess® is the LATAM holder subscription: sanitary registration, own-entity holder / importer of record, certified translations, and government submission fees inside one annual fee per country and device family, with a Submission Guarantee and a Trial-to-Market Bridge for clinical-trial clients. This page is a practitioner comparison, not a smear. Pure Global is a reasonable global RA / holder option in the markets it actually names. bioaccess® is the LATAM-only holder subscription.

    What Pure Global publishes about itself

    Pure Global’s public site is pureglobal.com. The firm positions local companies as authorized representative / license holder and publishes dedicated market pages for Argentina, Brazil, Colombia, Costa Rica, Mexico, and Peru (plus North America). On the Brazil, Mexico, and Colombia pages it sells the classic holder roles: Brazilian Registration Holder (BRH), Mexico Registration Holder (MRH), and INVIMA Legal Representative (with CCAA importer language on the Colombia page).

    Public entity language is strongest in those three markets. Pure Global names its own local companies in Brazil, Mexico, and Colombia — including Pure LATAM Colombia SAS (Bogotá), Pure Latam Mexico, S. de R.L. de C.V. (Mexico City), and a São Paulo office. The Peru page is more careful: it refers to “our local partner” while still using “Acting as your Holder.” Treat Peru — and, unless a named subsidiary appears, Argentina and Costa Rica — as partner-network coverage, not proven own-entity holder. That distinction matters when the registration is the only legal hook you have in-country.

    The commercial motion that makes Pure Global the closest analog is the fee. The Mexico page publishes “Starting at $2,000/year” and a fee calculator. The 5 February 2026 PR Newswire release, “Pure Global Introduces Industry-First Flat-Fee Pricing Model for Full-Service Global MedTech Market Access” (PR 302680246), describes a standard multi-year flat annual fee per registration and names Brazil, Mexico, and Colombia among the markets. The same release is explicit about what sits outside the fee: government fees, certified translations, and marketing materials. AI-assisted dossier workflows appear on the site. Pure Global is not a first-in-human CRO, and this comparison is not a CRO comparison.

    Facts above are taken from Pure Global’s public market and company pages and the 5 February 2026 release, retrieved 23 August 2026. No clients, emails, or extra country names are added.

    What “flat fee” has to mean on a LATAM holder file

    A Latin American sanitary registration is not a consulting memo. The regulator issues the certificate to an in-country legal person. That person is the titular / detentor / registration holder. In several markets the same person, or a closely tied license, is also the importer of record. If the holder is your distributor, the registration is commercial leverage. If the holder is an independent specialist, you can change distributors without rewriting the entire file — provided the agreement actually allows a transfer.

    The cash cost of that file is not only the holder’s time. Government submission fees are real invoices. Certified or sworn translations of IFUs, labels, and the technical file are often the largest hidden line, especially in Portuguese (Brazil) and Spanish with sworn-translator rules (Argentina, and frequently Brazil). A “flat annual fee” that excludes those two items is still a subscription. It is not the same product as a subscription that includes them.

    bioaccess® publishes that product as the LATAM Launch Subscription on bioaccessla.com/market-access. The model is: register and hold an already FDA-cleared (510(k)/PMA) or CE-marked device; act as in-country registration holder and importer of record through own local entities; include certified Spanish/Portuguese translations (sworn where required) and government submission fees; hold across 19 LATAM markets (six core markets detailed on the hub — ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID — with MINSA, ARCSA, DNM/SRS, and DIGEMAPS also named on the same page). Specific subscription rates are under review — contact for a quote. Multi-country discounts and a Trial-to-Market Bridge (20% off for clinical-trial clients, as published on the hub) sit on top of that structure. The LATAM Importer of Record guide is the country-rule companion.

    Two items sit outside the bioaccess® flat fee because they cannot be bundled honestly at a flat rate: Brazil BGMP manufacturing-site audit and telecom/EMC + RF homologation for wireless devices. Those are managed end-to-end and billed at vendor cost plus published G&A. That carve-out is on the market-access page. It is not the same carve-out as “government fees and certified translations extra.”

    Pure Global vs bioaccess® — what is inside the fee

    Dimension Pure Global (public) bioaccess®
    Product Global medtech market access; independent AR / license holder; AI dossier workflows LATAM Launch Subscription: sanitary registration + holder / IOR for already-cleared devices
    Public LATAM market pages Argentina, Brazil, Colombia, Costa Rica, Mexico, Peru Hub details Brazil, Colombia, Mexico, Argentina, Chile, Peru; coverage described as 19 LATAM markets; also names MINSA, ARCSA, DNM, DIGEMAPS
    Own local entity vs partner Own subsidiaries published for BR / MX / CO. Peru page: local partner. AR / CR not proven as own entities on the public pages reviewed Holds through own in-country entities; defined transfer provisions so the registration is not leverage
    Holder roles named BRH, MRH, INVIMA Legal Representative / CCAA importer language Registration holder / IOR across the LATAM set; country rules on the IOR guide
    Published fee Flat annual fee starting USD $2,000/year (Mexico page + 5 Feb 2026 PR) Flat all-inclusive annual subscription per country and device family; rates under review — contact for a quote
    Government submission fees Outside the published flat fee (PR) Included
    Certified translations Outside the published flat fee (PR) Included; in-house production; sworn where required (Brazil, Argentina)
    Marketing materials Outside the published flat fee (PR) Not sold as a creative-agency line; labels/IFU translation for the dossier is in the subscription
    Submission Guarantee No public equivalent found (dossier submitted on a committed schedule or a fee credit) Yes — submission workmanship; portion of that country’s annual fee credited if we miss what we control; full terms in the proposal
    Trial-to-Market Bridge Not a published FIH CRO + commercial registration stack Same partner from LATAM clinical trial to commercial registro sanitario (20% off for clinical-trial clients, as published)
    FIH CRO Not this product Separate live CRO practice; not what this page sells

    Read the table as a product map. If you need a global AR network and a published $2,000 starting number, Pure Global is a real option — just budget government fees and certified translations as extra, because they said so. If you need a LATAM holder who already put those two lines inside the annual fee, holds through own entities, and will still be the same firm if you ran (or will run) the trial in the region, that is bioaccess®.

    When Pure Global is the better fit

    • You want one global market-access vendor beyond LATAM and you are already buying their U.S./Canada or other-market stack.
    • You want a published starting price of $2,000/year and you are willing to pay government fees, certified translations, and marketing materials as separate invoices.
    • Your live markets are Brazil, Mexico, and/or Colombia, where Pure Global publishes own legal entities, and you do not need Andean / Southern Cone / Central American / Caribbean breadth on day one.
    • You want their AI dossier workflow as the primary production method.

    None of those are insults. They are scope. A global RA firm is allowed to be good at global RA.

    When the LATAM Launch Subscription is the better fit

    • The near-term milestone is commercial registro sanitario in Latin America, not a worldwide RA retainer.
    • You want government submission fees and certified translations inside the annual fee, not as change orders.
    • You want the holder to be an own local entity with a written transfer path — including markets where Pure Global’s public page still says “local partner.”
    • You need more than the six Pure Global LATAM market cards, or you need the importer-of-record rules (multi-importer vs single-IoR) documented country by country.
    • You already used, or will use, bioaccess® as the LATAM clinical-trial CRO and want one accountable partner through commercialization (Trial-to-Market Bridge).
    • You want a Submission Guarantee on the workmanship of the submission — not a promise that the agency will approve.

    How to run the RFP without inventing numbers

    1. Ask each vendor to list the LATAM countries where their own legal entity will be the titular, and the countries where a partner will. Demand the local company name.
    2. Ask for a written inclusion list: government fees, sworn translations (page count and languages), holder/IOR year one and renewal, agency queries, and transfer of the registration if you leave.
    3. Ask whether marketing-material production is in or out. Pure Global’s PR already answers “out.”
    4. Ask what happens if the dossier is late because of the vendor. A KPI is not a fee credit.
    5. Ask who holds the translation memory. bioaccess® publishes that the glossary is the manufacturer’s property.
    6. Do not treat “starting at $2,000” as all-in LATAM cost. Add the two excluded lines before you compare it to a bioaccess® quote.

    bioaccess® pricing remains under review — contact for a quote. Country pages and the compare set already live: Brazil / ANVISA, Mexico / COFEPRIS, Colombia / INVIMA, Argentina / ANMAT, Chile / ISP, vs Emergo by UL, vs Qserve Group.

    FAQ — Pure Global LATAM device registration

    Does Pure Global offer a flat annual fee?

    Yes, on its public Mexico page (starting at $2,000/year) and in the 5 February 2026 PR Newswire release. The same release states that government fees, certified translations, and marketing materials sit outside that fee.

    Does Pure Global act as BRH, MRH, or INVIMA Legal Rep?

    Those roles are on its Brazil, Mexico, and Colombia market pages. Own-entity language is published for those three countries. Peru is described with a local partner.

    Is Pure Global a first-in-human CRO?

    No. Do not hire it — or bioaccess®’s market-access team — as a substitute for an ISO 14155 FIH operating system. Commercial registration and investigational-device trials are different regulatory acts.

    What does bioaccess® include that the Pure Global flat fee excludes?

    On the published record: government registration submission fees and certified translations, plus own-entity holder across the 19-market LATAM coverage, a Submission Guarantee, and the Trial-to-Market Bridge. bioaccess® rates are under review — contact for a quote.

    Can a sponsor use both?

    Yes. A common pattern is a global RA firm for FDA/EU work and bioaccess® for LATAM holder / IOR. Documentation is built to reuse the FDA or CE technical file.

    Where should a sponsor start?

    Market access, IOR rules, then contact or book a meeting.

    Sources for competitor facts: pureglobal.com market and company pages and PR Newswire release 302680246 (5 February 2026), retrieved 23 August 2026. bioaccess® facts: bioaccessla.com/market-access and bioaccessla.com/latam-importer-of-record (July 2026 review). No invented clients, emails, statistics, or country lists.